Harriette Nadler

431 total citations
20 papers, 340 citations indexed

About

Harriette Nadler is a scholar working on Pharmacology, Molecular Medicine and Applied Microbiology and Biotechnology. According to data from OpenAlex, Harriette Nadler has authored 20 papers receiving a total of 340 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pharmacology, 8 papers in Molecular Medicine and 8 papers in Applied Microbiology and Biotechnology. Recurrent topics in Harriette Nadler's work include Antibiotics Pharmacokinetics and Efficacy (12 papers), Antibiotic Use and Resistance (8 papers) and Antibiotic Resistance in Bacteria (8 papers). Harriette Nadler is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (12 papers), Antibiotic Use and Resistance (8 papers) and Antibiotic Resistance in Bacteria (8 papers). Harriette Nadler collaborates with scholars based in United States, Canada and United Kingdom. Harriette Nadler's co-authors include Donald Pitkin, Michael J. Dowzicky, Joseph P. Iaconis, George H. Talbot, S. R. Kurtz, H George, John G. Baker, G.L. French, Robert C. Moellering and Donald E. Low and has published in prestigious journals such as Clinical Infectious Diseases, Journal of Clinical Microbiology and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Harriette Nadler

20 papers receiving 304 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Harriette Nadler United States 11 145 125 123 122 92 20 340
H. Drugeon France 10 208 1.4× 94 0.8× 147 1.2× 109 0.9× 136 1.5× 37 481
R R Packer United States 11 208 1.4× 119 1.0× 189 1.5× 76 0.6× 187 2.0× 22 418
D. Hoban Canada 11 114 0.8× 109 0.9× 161 1.3× 90 0.7× 180 2.0× 12 400
A Thabaut France 11 173 1.2× 86 0.7× 208 1.7× 64 0.5× 126 1.4× 76 395
B J McGrath United States 9 160 1.1× 115 0.9× 138 1.1× 68 0.6× 114 1.2× 10 351
F. C. Tenover United States 6 73 0.5× 128 1.0× 120 1.0× 147 1.2× 115 1.3× 8 368
Moellering Rc United States 8 105 0.7× 227 1.8× 96 0.8× 144 1.2× 128 1.4× 16 359
Renée S. Blosser-Middleton United States 14 164 1.1× 119 1.0× 167 1.4× 62 0.5× 277 3.0× 17 460
Arlene A. Obias United States 7 68 0.5× 144 1.2× 216 1.8× 76 0.6× 151 1.6× 8 377
Mel DeCorby Canada 8 110 0.8× 130 1.0× 216 1.8× 90 0.7× 130 1.4× 11 412

Countries citing papers authored by Harriette Nadler

Since Specialization
Citations

This map shows the geographic impact of Harriette Nadler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harriette Nadler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harriette Nadler more than expected).

Fields of papers citing papers by Harriette Nadler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harriette Nadler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harriette Nadler. The network helps show where Harriette Nadler may publish in the future.

Co-authorship network of co-authors of Harriette Nadler

This figure shows the co-authorship network connecting the top 25 collaborators of Harriette Nadler. A scholar is included among the top collaborators of Harriette Nadler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harriette Nadler. Harriette Nadler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Willey, Barbara, Ronald N. Jones, Allison McGeer, et al.. (1999). Practical approach to the identification of clinically relevant Enterococcus species. Diagnostic Microbiology and Infectious Disease. 34(3). 165–171. 42 indexed citations
3.
Eliopoulos, George M., Christine Wennersten, Howard S. Gold, et al.. (1998). Characterization of Vancomycin-Resistant Enterococcus faecium Isolates from the United States and Their Susceptibility In Vitro to Dalfopristin-Quinupristin. Antimicrobial Agents and Chemotherapy. 42(5). 1088–1092. 59 indexed citations
4.
Iaconis, Joseph P., et al.. (1997). Comparison of Antibacterial Activities of Meropenem and Six Other Antimicrobials Against Pseudomonas aeruginosa Isolates from North American Studies and Clinical Trials. Clinical Infectious Diseases. 24(Supplement 2). S191–S196. 25 indexed citations
5.
6.
Pitkin, Donald, Samuel E. Wilson, David L. Hemsell, et al.. (1995). Comparison of the Activity of Meropenem with That of Other Agents in the Treatment of Intraabdominal, Obstetric/Gynecologic, and Skin and Soft Tissue Infections. Clinical Infectious Diseases. 20(Supplement_2). S372–S375. 6 indexed citations
7.
Hutchison, Michael G., et al.. (1995). A compilation of meropenem tissue distribution data. Journal of Antimicrobial Chemotherapy. 36(suppl A). 43–56. 24 indexed citations
8.
Iaconis, Joseph P., et al.. (1995). Potential Factors Influencing Carbapenem Activity Against Bacteroides fragilis Group Isolates. Clinical Infectious Diseases. 20(Supplement_2). S361–S363. 2 indexed citations
9.
10.
Nadler, Harriette, et al.. (1993). A comparison of the in vitro postantibiotic effect of meropenem and imipenem versus selected enterobacteriaceae and other pathogens. Diagnostic Microbiology and Infectious Disease. 17(1). 71–73. 10 indexed citations
11.
Pitkin, Donald, et al.. (1993). Antibacterial Activity of Meropenem and Selected Comparative Agents Against Anaerobic Bacteria at Seven North American Centers. Clinical Infectious Diseases. 16(Supplement_4). S361–S366. 25 indexed citations
12.
Pitkin, Donald, et al.. (1989). Development of a meropenem susceptibility disc: drug content, preliminary interpretive and quality control criteria and potency bioassay. Journal of Antimicrobial Chemotherapy. 24(suppl A). 251–258. 4 indexed citations
13.
Nadler, Harriette, et al.. (1989). The postantibiotic effect of meropenem and imipenem on selected bacteria. Journal of Antimicrobial Chemotherapy. 24(suppl A). 225–231. 44 indexed citations
14.
Nadler, Harriette, William A. Curby, P Forgács, & Fred A. Rosenberg. (1989). Comparison of electronic and viability counting methods for determination of postantibiotic effect of oxacillin on Staphylococcus aureus. Antimicrobial Agents and Chemotherapy. 33(12). 2155–2156. 9 indexed citations
15.
Nadler, Harriette, et al.. (1985). Accuracy and reproducibility of the AutoMicrobic System Gram-Negative General Susceptibility-Plus Card for testing selected challenge organisms. Journal of Clinical Microbiology. 22(3). 355–360. 12 indexed citations
16.
Baker, John G., et al.. (1984). Candida lusitaniae: A new opportunistic pathogen of the urinary tract. Diagnostic Microbiology and Infectious Disease. 2(2). 145–149. 22 indexed citations
17.
Nadler, Harriette, C. Terrence Dolan, P Forgács, & H George. (1982). Brucella suis: an unusual cause of suppurative lymphadenitis in an outpatient. Journal of Clinical Microbiology. 16(3). 575–576. 8 indexed citations
18.
Bennett, Malcolm J., Harriette Nadler, & H George. (1979). New motility medium for nonfermenting bacilli.. PubMed. 45(2). 143–5. 1 indexed citations
19.
Nadler, Harriette, H George, & Jeremy J. Barr. (1979). Accuracy and reproducibility of the Oxi/Ferm system in identifying a select group of unusual gram-negative bacilli. Journal of Clinical Microbiology. 9(2). 180–185. 12 indexed citations
20.
Kung, S. D., M.A. Moscarello, John P. Williams, & Harriette Nadler. (1971). Renaturation of DNA from the blue-green alga Lyngbya sp.. Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis. 232(2). 252–254. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H. Drugeon Breakdown of academic impact, for papers by R R Packer Breakdown of academic impact, for papers by D. Hoban Breakdown of academic impact, for papers by A Thabaut Breakdown of academic impact, for papers by B J McGrath Breakdown of academic impact, for papers by F. C. Tenover Breakdown of academic impact, for papers by Moellering Rc Breakdown of academic impact, for papers by Renée S. Blosser-Middleton Breakdown of academic impact, for papers by Arlene A. Obias Breakdown of academic impact, for papers by Mel DeCorby
Rankless by CCL
2026